Top Banner
BY PROF. MOUSTAFA RIZK PROF. OF CLINICAL PATHOLOGY FACULTY OF MEDICINE, UNIVERSITY OF ALEXANDRIA. Laboratory Assessment Of Metabolic Disorders 10/12/17 06:03 1
73

Laboratory Assessment Of Metabolic Disorders

Jan 23, 2018

Download

Health & Medicine

Moustafa Rezk
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Laboratory Assessment Of Metabolic  Disorders

BYPROF. MOUSTAFA RIZK

PROF. OF CLINICAL PATHOLOGYFACULTY OF MEDICINE, UNIVERSITY OF ALEXANDRIA.

Laboratory Assessment Of Metabolic Disorders

10/12/17 06:03

1

Page 2: Laboratory Assessment Of Metabolic  Disorders

Laboratory assessment of disorders of carbohydrates metabolism

10/12/17 06:03

2

Page 3: Laboratory Assessment Of Metabolic  Disorders

When food is ingested there is a parallel rise in blood

glucose level. This increase in blood glucose is

sensed by the ß-cells in the pancreas and as a result,

insulin is secreted.

10/12/17 06:03

3

Page 4: Laboratory Assessment Of Metabolic  Disorders

FROM HYPER TO HYPOGLYC.

10/12/17 06:03

4

Page 5: Laboratory Assessment Of Metabolic  Disorders

Insulin circulates through the body and signals to

the major insulin sensitive organs: muscle, liver

and fat to increase their glucose intake . Insulin

simultaneously leads to a reduction of glucose

production from the liver and other organs . In this

way the hormone insulin counteracts the rise of

glucose in the blood returning the system to its

equilibrium.10/12/17 06:03

5

Page 6: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:03

6

Page 7: Laboratory Assessment Of Metabolic  Disorders

DIABETES MELLITUS

DEFINITION

Diabetes mellitus is a group of metabolic disorders

of carbohydrate metabolism in which glucose is

underutilized, producing hyperglycemia.

10/12/17 06:03

7

Page 8: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:03

8

Page 9: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:03

9

Page 10: Laboratory Assessment Of Metabolic  Disorders

CLASSIFICATION

1.Type 1 DM: autoimmune.

idiopathic.

2. Type 2 DM.

3. Other specific types (2 ry DM):

Acromegaly.

Cortisone treatment.

down’s syndrome

4. Gestational DM.

5. Impaired glucose tolerance.

6. Impaired fasting glucose.10/12/17 06:03

10

Page 11: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:03

11

Page 12: Laboratory Assessment Of Metabolic  Disorders

CRTERIA OF DIAGNOSIS

Type 2 DM. Classical symptoms of diabetes and RBG> 200 mg/dL. OR

FBG ≥ 126 mg/dL. OR

2 hour OGTT ≥ 200 mg/dL.

Gestational DM:

By OGTT: two out of four criteria :

FBG ≥ 105 mg/dL

1 hour ≥ 190 mg/dL.

2 hour ≥ 165 mg/dL.

3 hour ≥ 145 mg/dL.

10/12/17 06:03

12

Page 13: Laboratory Assessment Of Metabolic  Disorders

Impaired glucose tolerance: Two criteria

FBG < 126 mg/dL

2 h OGTT 140-199 mg/dL.

Impaired fasting glucose: Two criteria

FBG 111-125 mg/dL

2 h OGTT < 140 mg/dL

10/12/17 06:03

13

Page 14: Laboratory Assessment Of Metabolic  Disorders

ROLE OF THE LAB IN DIABETES MELLITUS

I. Diagnosis: Immunological markers:

-Islet cell antibodies (ICA).

-Insulin auto-antibodies ( IAA).

Genetic markers (e.g., HLA).

Insulin secretion.

Blood glucose.

Oral glucose tolerance curve.

Urine ketones.

Others (e.g., C peptide).

10/12/17 06:03

14

Page 15: Laboratory Assessment Of Metabolic  Disorders

II. Management:

Acute:

Glucose ( blood- urine)

Ketones (blood-urine)

Acid-base status (PH, bicarbonate).

Lactate.

Other abnormalities related to cellular dehydration or

therapy ( K, Na, phosphate, osmolality)

10/12/17 06:03

15

Page 16: Laboratory Assessment Of Metabolic  Disorders

Chronic: Glucose (blood-urine)

Glycated proteins(HbA1C-fructosamine)

Urinary protein

Urinary albumin excretion

Proteinuria

Evaluation of complications( renal function, TG, Cholesterol)

Evaluation of pancreas transplant ( C peptide, insulin)

10/12/17 06:03

16

Page 17: Laboratory Assessment Of Metabolic  Disorders

Laboratory assessment of

disorders of Lipids metabolism

10/12/17 06:03

17

Page 18: Laboratory Assessment Of Metabolic  Disorders

18

Major lipids present in plasma:

Fatty Acids Triglycerides Cholesterol Phospholipids

10/12/17 06:03

Page 19: Laboratory Assessment Of Metabolic  Disorders

19

Triglycerides

Normal level < 160 mg/dl

10/12/17 06:03

Page 20: Laboratory Assessment Of Metabolic  Disorders

20

Triglyceride Structure

10/12/17 06:03

Page 21: Laboratory Assessment Of Metabolic  Disorders

21Cholesterol

Normal level < 200 mg / dl

10/12/17 06:03

Page 22: Laboratory Assessment Of Metabolic  Disorders

22

10/12/17 06:03

Page 23: Laboratory Assessment Of Metabolic  Disorders

23

10/12/17 06:03

Page 24: Laboratory Assessment Of Metabolic  Disorders

24

10/12/17 06:03

Page 25: Laboratory Assessment Of Metabolic  Disorders

25

10/12/17 06:03

Page 26: Laboratory Assessment Of Metabolic  Disorders

26

Classification of Lipoproteins

10/12/17 06:03

Page 27: Laboratory Assessment Of Metabolic  Disorders

27

Lipoprotein metabolism

Exogenous TG Chylomicrons(CM)→ Endogenous TG VLDL→ Exogenous Cholesterol CM→ Endogenous Cholesterol LDL→ Reverse Cholesterol Transport

10/12/17 06:03

Page 28: Laboratory Assessment Of Metabolic  Disorders

28

10/12/17 06:03

Page 29: Laboratory Assessment Of Metabolic  Disorders

29

10/12/17 06:03

Page 30: Laboratory Assessment Of Metabolic  Disorders

30

Selection of patients for investigations

CHD & vascular disease Family history of coronary disease Risk factors for CHD Clinical features of hyperlipideamia Lipeamic plasma

10/12/17 06:03

Page 31: Laboratory Assessment Of Metabolic  Disorders

31

Blood sampling for lipid studies

Serum or plasma 12-14 h fasting for TG,HDL & LDL Fasting or no fasting for total cholesterol Usual diet for 2 weeks Avoid vigorous exercise for 1 day

10/12/17 06:03

Page 32: Laboratory Assessment Of Metabolic  Disorders

Serum Cholesterol 140-200 mg/dL Serum Triglycerides: 50-159 mg/dL. HDL-C 35-80 mg/dL

<35 High risk, > 60 Low risk

LDL-C up to 130 mg/dL < 130 Low risk, >160 High risk

HDL/ Total cholesterol >26% Low risk, < 16 % High risk

LDL/HDL > 5% High risk, < 3 % Low risk

Total lipids up to 550 mg/dL.10/12/17 06:03

32

Page 33: Laboratory Assessment Of Metabolic  Disorders

LIPOPROTEIN ELECTROPHORESIS

During electrophoresis, the lipoproteins separate (in order of decreasing mobility) into 4 fractions : alpha, pre-beta, beta lipoproteins and chylomicrons

10/12/17 06:03

33

Page 34: Laboratory Assessment Of Metabolic  Disorders

VALUE OF LIPOGRAM

Increased band                  Patterns

Chylomicrons I

Beta and pre-beta IIb

Broad beta III

Pre-beta IV

Pre-beta and chylomicrons V

Fredrickson DS. Circulation 1975; 51: 209-211.

10/12/17 06:03

34

Page 35: Laboratory Assessment Of Metabolic  Disorders

Laboratory assessment of some protein disorders

10/12/17 06:03

35

Page 36: Laboratory Assessment Of Metabolic  Disorders

NORMAL PROTEIN BANDS

10/12/17 06:03

36

Page 37: Laboratory Assessment Of Metabolic  Disorders

NORMAL PROTEIN BANDS

Albumin 50-60 %α1 Glob 3 - 5 %α2 Glob 5 - 8 %β Glob 8 -12 %Gamma 12-22 %

10/12/17 06:03 37

Page 38: Laboratory Assessment Of Metabolic  Disorders

PROTEIN DENSITY VERSUS THE CURVE

10/12/17 06:03

38

Page 39: Laboratory Assessment Of Metabolic  Disorders

INCREASED ALPHA GLOBULINS

10/12/17 06:03

39

Page 40: Laboratory Assessment Of Metabolic  Disorders

Patterns of Serum Protein Electrophoresis

Alb A1 A2 B GammaChronic N,D N,E E N E infalmmatoryrespnceAcute N,D E E N N,DinflammatoryrespnceSubacuteN,D N E N N

10/12/17 06:03

40

Page 41: Laboratory Assessment Of Metabolic  Disorders

POLYCLONAL GAMMOPATHY WITH DECREASED ALBUMIN

10/12/17 06:03

41

Page 42: Laboratory Assessment Of Metabolic  Disorders

INCREASED GAMMA GLOBULINS

10/12/17 06:03

42

Page 43: Laboratory Assessment Of Metabolic  Disorders

Patterns of Serum Protein Electrophoresis

Alb A1 A2 B GammaHepatic D N N,D bridging cirrhosisMonoclo N,E N,D N N M spikegammopathyMonoclo N,E N,D N M spike N,DgammopathyBiclonal N,E N,D N M spike M spigammopathy

10/12/17 06:03

43

Page 44: Laboratory Assessment Of Metabolic  Disorders

ACUTE PHASE REACTANTS:

C-reactive protein (CRP). Antiprotease inhibitors. Ceruloplasmin. α1 –acid glycoprotein. Fibrinogen. Haptoglobin. C3.

10/12/17 06:03

44

Page 45: Laboratory Assessment Of Metabolic  Disorders

Negative acute phase reactants:

Albumin. Transferrin.

10/12/17 06:03

45

Page 46: Laboratory Assessment Of Metabolic  Disorders

Laboratory assessment of Mineral and bone metabolism

10/12/17 06:03

46

Page 47: Laboratory Assessment Of Metabolic  Disorders

Minerals important in our body include Minerals important in our body include ::

1- Calcium1- Calcium

2- Phosphorus2- Phosphorus

3- Magnesium3- Magnesium

10/12/17 06:03

47

Page 48: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0348

Page 49: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0349

Page 50: Laboratory Assessment Of Metabolic  Disorders

11.Parathyroid Hormone:.Parathyroid Hormone:

(A)(A)Synthesis and Secretion :Synthesis and Secretion : PTH is synthesized and secreted by the four PTH is synthesized and secreted by the four

parathyroid glands located on the thyroid parathyroid glands located on the thyroid capsule.capsule.

The conc. of free calcium in blood or extra-The conc. of free calcium in blood or extra-cellular fluid is the primary regulator of PTH cellular fluid is the primary regulator of PTH synthesis and secretion.synthesis and secretion.

Magnesium and 1,25(OH)2 D has a minor Magnesium and 1,25(OH)2 D has a minor influence.influence.

10/12/17 06:03

50

Page 51: Laboratory Assessment Of Metabolic  Disorders

(B) Biological Action :Biological Action : PTH increases total and free Ca++, decreases

plasma Ph and increases urinary excretion of inorganic Ph.

On bones:- PTH stimulates bone resorption or bone

formation.

10/12/17 06:03

51

Page 52: Laboratory Assessment Of Metabolic  Disorders

3) In the kidney, PTH : Increases Ca++ reabsorption in the D.C.T. Decreases reabsorption of Ph by proximal T. Inhibits Na+ - H+ antiporter activity which

favors a mild hypercholermic metabolic acidosis in hyperparathyroid states.

Induces 25-hydroxyvit.D – 1α hydrolase, increasing the production of 1,25(OH)2 D which stimulates intestinal absorption of both Calcium and Phosphate.

10/12/17 06:03

52

Page 53: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0353

Page 54: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0354

Page 55: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:03

55

Page 56: Laboratory Assessment Of Metabolic  Disorders

(C) Clinical Significance :(C) Clinical Significance :

Determination of PTH is useful : In the D.D. of both hypocalcaemia &

hypercalcaemia. For assessing parathyroid function in renal

failure. For evaluating parathyroid function in bone

and mineral disorders.

10/12/17 06:03

56

Page 57: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0357

Page 58: Laboratory Assessment Of Metabolic  Disorders

22.Vit. D & its metabolites.Vit. D & its metabolites::

(A)(A) Synthesis :Synthesis : Vit. D is produced endogenously by exposure of

skin to sunlight and is absorbed from food.

It is then metabolized to its main circulatory form, 25-hydroxyvit. D and then to its biologically active form, 1,25(OH)2 D which is the hormone regulating calcium and phosphate metabolism.

10/12/17 06:03

58

Page 59: Laboratory Assessment Of Metabolic  Disorders

Vit. D & its metabolitesVit. D & its metabolites

10/12/17 06:03

59

Page 60: Laboratory Assessment Of Metabolic  Disorders

Vit. D & its metabolitesVit. D & its metabolites

(B) Biological Actions of 1,25(OH)(B) Biological Actions of 1,25(OH)2 2 D :D :

Ca and ph. concentrations in serum are maintained by the actions of 1,25(OH)2 D on :

1.intestine.

2.bone.

3. kidney.

4.parathyroid glands.

10/12/17 06:03

60

Page 61: Laboratory Assessment Of Metabolic  Disorders

Vit. D & its metabolitesVit. D & its metabolites

1) In the Intestine :

1,25(OH)2 D stimulates calcium absorption, by the duodenum & phosphate absorption by the jujenum and ileum.

2) On bone :

1,25(OH)2 D increases bone resorption by stimulating osteaclastic differentiation

10/12/17 06:03

61

Page 62: Laboratory Assessment Of Metabolic  Disorders

Vit. D & its metabolitesVit. D & its metabolites

3)In the Kidney 3)In the Kidney ::

It inhibits its own synthesis and stimulates its metabolism.

4)On parathyroid glands 4)On parathyroid glands ::

It inhibits the synthesis and secretion of PTH.

10/12/17 06:03

62

Page 63: Laboratory Assessment Of Metabolic  Disorders

Vit. D & its metabolitesVit. D & its metabolites

(C) Clinical Significance :(C) Clinical Significance :Knowing the concentration of 25(OH)D (which

is the best indication of vit. D nutritional status )because it is:

1.the main circulatory form 2.varies less from day to day with sun exposure &diet 3.easily measuredis useful in evaluating :a) hypocalcaemiab) vit. D statusc) bone diseased) other disorders of mineral metabolism

10/12/17 06:03

63

Page 64: Laboratory Assessment Of Metabolic  Disorders

10/12/17 06:0364

Page 65: Laboratory Assessment Of Metabolic  Disorders

3.CalcitoninCalcitonin:

(A) Secretion:

Calcitonin is secreted by the parafollicular or C cells which are distributed throughout the thyroid glands.

10/12/17 06:03

65

Page 66: Laboratory Assessment Of Metabolic  Disorders

CalcitoninCalcitonin

(B) Biological Actions : Pharmacological doses of calcitonin decrease

serum calcium and ph. concentrations by inhibiting osteoclastic bone resorption.

Multiple forms of Circulating calcitonin have been reported in patients with medullary thyroid carcinomas which occurs as a part of the syndromes of MEN-2A, MEN-2B and familial MTC.

10/12/17 06:03

66

Page 67: Laboratory Assessment Of Metabolic  Disorders

MARKERS OF BONE METABOLISM

MARKERS OF BONE FORMATION 1-OSTEOCALCIN

2-ALKALINE PHOSPHATASE

3-PROCOLLAGEN PEPTIDES

MARKERS OF BONE RESORPTION

1-COLLAGEN CROSS LINKS

2-TARTARATE RESISTENT ACID P

10/12/17 06:03

67

Page 68: Laboratory Assessment Of Metabolic  Disorders

MARKERS OF BONE METABOLISM

3-URINARY GALACTOSYL HYDROXYLYSIN

4-URINARY HYDROXYPROLINE

10/12/17 06:03

68

Page 69: Laboratory Assessment Of Metabolic  Disorders

BONE METABOLIC DISORDERS

OSTEOPOROSIS OSTEOMALACIA PAGETS DISEASE RENAL OSTEODYSTROPHY

10/12/17 06:03

69

Page 70: Laboratory Assessment Of Metabolic  Disorders

Paget’s disease

Paget’s (pronounced paj-ets) disease affects bones. Throughout a person’s life bone is constantly breaking

down and growing back. With Paget’s disease the normal process of bone growth is changed. The bone breaks down more quickly, and when it grows again it is softer than normal bone.

Soft bones can bend or break more easily. The area affected by Paget’s disease can become shorter because the bone bends.

With Paget’s disease the bone can also grow larger than before.

Paget’s disease can affect any bone, but usually affects the skull, the hip and pelvis bones and bones in the legs and back.

10/12/17 06:03

70

Page 71: Laboratory Assessment Of Metabolic  Disorders

Lab Studies

Biochemical indices reveal elevated alkaline phosphatase levels of bone origin, due to increased osteoblastic activity and bone formation.

In limited Paget disease, the alkaline phosphatase level may be within the reference range. Procollagen I N-terminal peptide (PINP) recently has emerged as a sensitive serum marker for bone formation.

Many patients with elevated alkaline phosphatase levels have been found to have osteocalcin measurements within the reference range.

10/12/17 06:03

71

Page 72: Laboratory Assessment Of Metabolic  Disorders

In Paget disease, urinary hydroxyproline levels are elevated as they reflect increased osteoclastic activity and bone resorption.

10/12/17 06:03

72

Page 73: Laboratory Assessment Of Metabolic  Disorders

THANK YOU PROF./MOUSTAFA RIZK

10/12/17 06:03

73